Hilmir Asgeirsson1,2, Anders Thalme1, Ola Weiland1,2. 1. a Department of Infectious Diseases , Karolinska University Hospital , Stockholm , Sweden. 2. b Unit of Infectious Diseases, Department of Medicine Huddinge , Karolinska Institutet , Stockholm , Sweden.
Abstract
PURPOSE: To review the epidemiology of Staphylococcus aureus bacteraemia (SAB) and endocarditis (SAE), and discuss the short- and long-term outcome. Materials and methods: A literature review of the epidemiology of SAB and SAE. RESULTS: The reported incidence of SAB in Western countries is 16-41/100,000 person-years. Increasing incidence has been observed in many regions, in Iceland by 27% during 1995-2008. The increase is believed to depend on changes in population risk factors and possibly better and more frequent utilization of diagnostic procedures. S. aureus is now the leading causes of infective endocarditis (IE) in many regions of the world. It accounts for 15-40% of all IE cases, and the majority of cases in people who inject drugs (PWID). Recently, the incidence of SAE in PWID in Stockholm, Sweden, was found to be 2.5/1000 person-years, with an in-hospital mortality of 2.5% in PWID as compared to 15% in non-drug users. The 30-day mortality associated with SAB amounts to 15-25% among adults in Western countries, but is lower in children (0-9%). Mortality associated with SAE is high (generally 20-30% in-hospital mortality), and symptomatic cerebral embolizations are common (12-35%). The 1-year mortality reported after SAB and SAE is 19-62% and reflects deaths from underlying diseases and complications caused by the infection. In a subset of SAE cases, valvular heart surgery is needed (15-45%), but active intravenous drug use seems to be a reason to refrain from surgery. Despite its importance, there are insufficient data on the optimal management of SAB and SAE, especially on the required duration of antibiotic therapy. Conclusions: The epidemiology of SAB and SAE has been changing in the past decades. They still carry a substantial morbidity and mortality. Intensified studies on treatment are warranted for improving patient outcome.
PURPOSE: To review the epidemiology of Staphylococcus aureus bacteraemia (SAB) and endocarditis (SAE), and discuss the short- and long-term outcome. Materials and methods: A literature review of the epidemiology of SAB and SAE. RESULTS: The reported incidence of SAB in Western countries is 16-41/100,000 person-years. Increasing incidence has been observed in many regions, in Iceland by 27% during 1995-2008. The increase is believed to depend on changes in population risk factors and possibly better and more frequent utilization of diagnostic procedures. S. aureus is now the leading causes of infective endocarditis (IE) in many regions of the world. It accounts for 15-40% of all IE cases, and the majority of cases in people who inject drugs (PWID). Recently, the incidence of SAE in PWID in Stockholm, Sweden, was found to be 2.5/1000 person-years, with an in-hospital mortality of 2.5% in PWID as compared to 15% in non-drug users. The 30-day mortality associated with SAB amounts to 15-25% among adults in Western countries, but is lower in children (0-9%). Mortality associated with SAE is high (generally 20-30% in-hospital mortality), and symptomatic cerebral embolizations are common (12-35%). The 1-year mortality reported after SAB and SAE is 19-62% and reflects deaths from underlying diseases and complications caused by the infection. In a subset of SAE cases, valvular heart surgery is needed (15-45%), but active intravenous drug use seems to be a reason to refrain from surgery. Despite its importance, there are insufficient data on the optimal management of SAB and SAE, especially on the required duration of antibiotic therapy. Conclusions: The epidemiology of SAB and SAE has been changing in the past decades. They still carry a substantial morbidity and mortality. Intensified studies on treatment are warranted for improving patient outcome.
Authors: Maria Audilene de Freitas; Rafael Pereira da Cruz; Antonia Thassya Lucas Dos Santos; José Weverton Almeida-Bezerra; Antonio Júdson Targino Machado; Joycy Francely Sampaio Dos Santos; Janaina Esmeraldo Rocha; Aline Augusti Boligon; Camila Fonseca Bezerra; Thiago Sampaio de Freitas; Maria Karollyna do Nascimento Silva; Ana Cleide Alcântara Morais Mendonça; José Galberto Martins da Costa; Henrique Douglas Melo Coutinho; Francisco Assis Bezerra da Cunha; Jaime Ribeiro Filho; Maria Flaviana Bezerra Morais-Braga Journal: 3 Biotech Date: 2022-02-07 Impact factor: 2.406
Authors: Ana Marques; Inês Cruz; Daniel Caldeira; Sofia Alegria; Ana Catarina Gomes; Ana Luísa Broa; Isabel João; Hélder Pereira Journal: Arq Bras Cardiol Date: 2020-01 Impact factor: 2.000
Authors: Robert Strengen Bigseth; Håkon Sandholdt; Andreas Petersen; Christian Østergaard; Thomas Benfield; Louise Thorlacius-Ussing Journal: Microbiol Spectr Date: 2022-04-19